Stay updated on Ganaxolone in PCDH19 Epilepsy Clinical Trial
Sign up to get notified when there's something new on the Ganaxolone in PCDH19 Epilepsy Clinical Trial page.

Latest updates to the Ganaxolone in PCDH19 Epilepsy Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedIntroduces a Locations section with state locations (Arizona, California, Georgia, Indiana, Massachusetts, New Jersey, Ohio) and updates the revision to v3.3.3. Individual state location subsections and the HHS Vulnerability Disclosure text were removed.SummaryDifference0.9%

- Check25 days agoNo Change Detected
- Check47 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.2.0.SummaryDifference0.1%

- Check54 days agoChange DetectedThe government funding lapse notice has been removed from the page. The core study details, locations, and eligibility criteria remain unchanged.SummaryDifference0.4%

- Check68 days agoChange DetectedMinor UI tweaks and formatting adjustments were observed, with no substantive updates to the study details (e.g., inclusion criteria, outcomes, or enrollment). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check97 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that NI H Clinical Center is open and where to check status.SummaryDifference4%

- Check104 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%

Stay in the know with updates to Ganaxolone in PCDH19 Epilepsy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ganaxolone in PCDH19 Epilepsy Clinical Trial page.